Transcatheter Aortic Valve Replacement in Special Population Groups

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment landscape for severe symptomatic aortic stenosis among all surgical risk groups. Thus, following the expansion of TAVR use and constant improvements in TAVR platforms and implantation techniques, implementation has been extended to special population groups that were previously underrepresented in clinical trials. This review evaluates the role of TAVR in patients with unique clinical considerations, including those with active malignancies, psychiatric disorders, and advanced organ dysfunction. By examining current literature, we provide insights into the safety, efficacy, appropriateness, and specific challenges associated with TAVR in these patient groups.